The cellular adaptations to hypoxia as novel therapeutic targets in childhood cancer

Cancer Treatment Reviews

Volumn 34, Issue 3, 2008, Pages 231-246

  Adamski, J K ^a,b   Estlin, E J ^b   Makin, G W J ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Childhood cancer; Hypoxia; Novel agents

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 2 METHOXYESTRADIOL; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ACETAZOLAMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; ECHINOMYCIN; ETOPOSIDE; GELDANAMYCIN; MELPHALAN; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; NSC 13502; OXYGEN; PACLITAXEL; SORAFENIB; SUNITINIB; TIRAPAZAMINE; TOPOTECAN; UNINDEXED DRUG; VATALANIB; VINCRISTINE;

ANAEROBIC GLYCOLYSIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW TOXICITY; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CELL HYPOXIA; CELL PH; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENERGY METABOLISM; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; GENOMIC INSTABILITY; GLIOMA; HEAD AND NECK CARCINOMA; HUMAN; HYPERBARIC OXYGEN; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LUNG SMALL CELL CANCER; LUNG TOXICITY; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; MUSCLE CRAMP; NEPHRECTOMY; NEPHROBLASTOMA; NEUROBLASTOMA; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PROGNOSIS; PROTEIN EXPRESSION; RADIATION RESPONSE; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ADAPTATION, PHYSIOLOGICAL; CELL HYPOXIA; CHILD; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; GENOMIC INSTABILITY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 42649083289     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.11.005     Document Type: Review

References (228)

1. Gatta G., Corazziari I., Magnani C., et al. Childhood cancer survival in Europe. Ann Oncol 14 Suppl. 5 (2003) v119-v127
2. Teicher B.A. Hypoxia and drug resistance. Cancer Metast Rev 13 2 (1994) 139-168
3. Brown L.M., Cowen R.L., Debray C., et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69 2 (2006) 411-418
4. Tatum J.L., Kelloff G.J., Gillies R.J., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82 10 (2006) 699-757
5. Semenza G.L. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology [Bethesda] 19 (2004) 176-182
6. Kim J.W., Gao P., and Dang C.V. Effects of hypoxia on tumor metabolism. Cancer Metast Rev 26 2 (2007) 291-298
7. Sullivan R., and Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metast Rev 26 2 (2007) 319-331
8. Greijer A.E., and van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57 10 (2004) 1009-1014
9. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 22 (1999) 5830-5835
10. Vaupel P., Kallinowski F., and Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49 23 (1989) 6449-6465
11. Haugland H.K., Vukovic V., Pintilie M., et al. Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys 53 4 (2002) 854-861
12. Cvetkovic D., Movsas B., Dicker A.P., et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 57 4 (2001) 821-825
13. Airley R., Loncaster J., Davidson S., et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7 4 (2001) 928-934
14. Loncaster J.A., Harris A.L., Davidson S.E., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61 17 (2001) 6394-6399
15. Hedley D., Pintilie M., Woo J., et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 9 15 (2003) 5666-5674
16. Mayer A., Hockel M., Wree A., and Vaupel P. Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers. Clin Cancer Res 11 7 (2005) 2768-2773
17. Vaupel P., and Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metast Rev 26 2 (2007) 225-239
18. Wellmann S., Guschmann M., Griethe W., et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 18 5 (2004) 926-933
19. Eggert A., Ikegaki N., Kwiatkowski J., et al. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6 5 (2000) 1900-1908
20. Webster K.A. Evolution of the coordinate regulation of glycolytic enzyme genes by hypoxia. J Exp Biol 206 Pt 17 (2003) 2911-2922
21. 2 tension. Proc Natl Acad Sci USA 92 12 (1995) 5510-5514
22. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 6733 (1999) 271-275
23. Tanimoto K., Makino Y., Pereira T., and Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. Embo J 19 16 (2000) 4298-4309
24. Ohh M., Park C.W., Ivan M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2 7 (2000) 423-427
25. 2-regulated prolyl hydroxylation. Science 292 5516 (2001) 468-472
26. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2 1 (2002) 38-47
27. Karth J., Ferrer F.A., Perlman E., et al. Coexpression of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in Wilms' tumor. J Pediatr Surg 35 12 (2000) 1749-1753
28. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 12 (2001) 3995-4004
29. Lim J.H., Lee E.S., You H.J., et al. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 23 58 (2004) 9427-9431
30. Bardos J.I., and Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26 3 (2004) 262-269
31. Airley R.E., and Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53 4 (2007) 233-256
32. Minn H., Lapela M., Klemi P.J., et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38 12 (1997) 1907-1911
33. Macheda M.L., Rogers S., and Best J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202 3 (2005) 654-662
34. Lin Z., Weinberg J.M., Malhotra R., et al. GLUT-1 reduces hypoxia-induced apoptosis and JNK pathway activation. Am J Physiol Endocrinol Metab 278 5 (2000) E958-E966
35. Airley R.E., Phillips R.M., Evans A.E., et al. Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int J Oncol 26 6 (2005) 1477-1484
36. Semenza G.L., Roth P.H., Fang H.M., and Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269 38 (1994) 23757-23763
37. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12 2 (1998) 149-162
38. Smith T.A. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 57 2 (2000) 170-178
39. Mathupala S.P., Rempel A., and Pedersen P.L. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276 46 (2001) 43407-43412
40. Pastorino J.G., Shulga N., and Hoek J.B. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 277 9 (2002) 7610-7618
41. Koukourakis M.I., Giatromanolaki A., and Sivridis E. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol 24 4 (2003) 199-202
42. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89 5 (2003) 877-885
43. Koukourakis M.I., Giatromanolaki A., Simopoulos C., Polychronidis A., and Sivridis E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metast 22 1 (2005) 25-30
44. Martinez-Zaguilan R., Seftor E.A., Seftor R.E., et al. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metast 14 2 (1996) 176-186
45. Schlappack O.K., Zimmermann A., and Hill R.P. Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br J Cancer 64 4 (1991) 663-670
46. Swietach P., Vaughan-Jones R.D., and Harris A.L. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metast Rev 26 2 (2007) 299-310
47. Beasley N.J., Wykoff C.C., Watson P.H., et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61 13 (2001) 5262-5267
48. Wykoff C.C., Beasley N.J., Watson P.H., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60 24 (2000) 7075-7083
49. Ullah M.S., Davies A.J., and Halestrap A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 281 14 (2006) 9030-9037
50. Shimoda L.A., Fallon M., Pisarcik S., Wang J., and Semenza G.L. HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 291 5 (2006) L941-L949
51. Sivridis E., Giatromanolaki A., and Koukourakis M.I. The vascular network of tumours - what is it not for?. J Pathol 201 2 (2003) 173-180
52. Thompson W.D., Shiach K.J., Fraser R.A., McIntosh L.C., and Simpson J.G. Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth. J Pathol 151 4 (1987) 323-332
53. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. 'Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J Pathol 192 2 (2000) 140-149
54. Liao D., and Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metast Rev 26 2 (2007) 281-290
55. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 9 (1996) 4604-4613
56. Gerber H.P., Condorelli F., Park J., and Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272 38 (1997) 23659-23667
57. Das B., Yeger H., Tsuchida R., et al. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 65 16 (2005) 7267-7275
58. Carmeliet P., Dor Y., Herbert J.M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 6692 (1998) 485-490
59. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 6560 (1996) 88-91
60. Bruick R.K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 97 16 (2000) 9082-9087
61. Kilic M., Kasperczyk H., Fulda S., and Debatin K.M. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 26 14 (2007) 2027-2038
62. Sowter H.M., Ratcliffe P.J., Watson P., Greenberg A.H., and Harris A.L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 61 18 (2001) 6669-6673
63. Vande Velde C., Cizeau J., Dubik D., et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 20 15 (2000) 5454-5468
64. Soengas M.S., Alarcon R.M., Yoshida H., et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284 5411 (1999) 156-159
65. Hammond E.M., Denko N.C., Dorie M.J., Abraham R.T., and Giaccia A.J. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 22 6 (2002) 1834-1843
66. Warnecke C., Griethe W., Weidemann A., et al. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. Faseb J 17 9 (2003) 1186-1188
67. Hammond E.M., and Giaccia A.J. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331 3 (2005) 718-725
68. Rossler J., Schwab M., Havers W., and Schweigerer L. Hypoxia promotes apoptosis of human neuroblastoma cell lines with enhanced N-myc expression. Biochem Biophys Res Commun 281 2 (2001) 272-276
69. Nelson D.A., Tan T.T., Rabson A.B., et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 18 17 (2004) 2095-2107
70. Erler J.T., Cawthorne C.J., Williams K.J., et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24 7 (2004) 2875-2889
71. Kalra R., Jones A.M., Kirk J., Adams G.E., and Stratford I.J. The effect of hypoxia on acquired drug resistance and response to epidermal growth factor in Chinese hamster lung fibroblasts and human breast-cancer cells in vitro. Int J Cancer 54 4 (1993) 650-655
72. Hussein D., Estlin E.J., Dive C., and Makin G.W. Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 5 9 (2006) 2241-2250
73. Lemasters J.J., and Holmuhamedov E. Voltage-dependent anion channel (VDAC) as mitochondrial governator - thinking outside the box. Biochim Biophys Acta 1762 2 (2006) 181-190
74. Gwak G.Y., Yoon J.H., Kim K.M., et al. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 42 3 (2005) 358-364
75. Pi X., Garin G., Xie L., et al. BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor 1alpha. Circ Res 96 11 (2005) 1145-1151
76. Hiraga T., Kizaka-Kondoh S., Hirota K., Hiraoka M., and Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 67 9 (2007) 4157-4163
77. Ide T., Kitajima Y., Miyoshi A., et al. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol 14 9 (2007) 2600-2607
78. Matsuyama T., Nakanishi K., Hayashi T., et al. Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Sci 96 3 (2005) 176-182
79. Chen W.T., Huang C.J., Wu M.T., et al. Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. Jpn J Clin Oncol 35 4 (2005) 207-213
80. Krishnamachary B., Zagzag D., Nagasawa H., et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66 5 (2006) 2725-2731
81. Munoz-Najar U.M., Neurath K.M., Vumbaca F., and Claffey K.P. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 25 16 (2006) 2379-2392
82. Krishnamachary B., Berg-Dixon S., Kelly B., et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63 5 (2003) 1138-1143
83. Fujiwara S., Nakagawa K., Harada H., et al. Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 30 4 (2007) 793-802
84. Miyoshi A., Kitajima Y., Ide T., et al. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner. Int J Oncol 29 6 (2006) 1533-1539
85. Chen H.H., Su W.C., Lin P.W., Guo H.R., and Lee W.Y. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res Treat 103 2 (2007) 167-175
86. Wang T., Niki T., Goto A., et al. Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway. Cancer Sci 98 4 (2007) 506-511
87. Zagzag D., Nomura M., Friedlander D.R., et al. Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 196 2 (2003) 394-402
88. Niizeki H., Kobayashi M., Horiuchi I., et al. Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br J Cancer 86 12 (2002) 1914-1919
89. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237 (1999) 97-132
90. Tong R.T., Boucher Y., Kozin S.V., et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64 11 (2004) 3731-3736
91. Weis S., Cui J., Barnes L., and Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167 2 (2004) 223-229
92. Kucia M., Reca R., Miekus K., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23 7 (2005) 879-894
93. Pan J., Mestas J., Burdick M.D., et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 5 (2006) 56
94. Yuan J., Narayanan L., Rockwell S., and Glazer P.M. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 60 16 (2000) 4372-4376
95. Russo C.A., Weber T.K., Volpe C.M., et al. An anoxia inducible endonuclease and enhanced DNA breakage as contributors to genomic instability in cancer. Cancer Res 55 5 (1995) 1122-1128
96. Coquelle A., Toledo F., Stern S., Bieth A., and Debatisse M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 2 2 (1998) 259-265
97. Koshiji M., To K.K., Hammer S., et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 17 6 (2005) 793-803
98. Cummins E.P., and Taylor C.T. Hypoxia-responsive transcription factors. Pflugers Arch 450 6 (2005) 363-371
99. Wu X., Senechal K., Neshat M.S., Whang Y.E., and Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95 26 (1998) 15587-15591
100. Bindra R.S., Gibson S.L., Meng A., et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 65 24 (2005) 11597-11604
101. 2 tension. Am J Physiol 271 4 Pt 1 (1996) C1172-C1180
102. Kotch L.E., Iyer N.V., Laughner E., and Semenza G.L. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 209 2 (1999) 254-267
103. Provot S., Zinyk D., Gunes Y., et al. Hif-1alpha regulates differentiation of limb bud mesenchyme and joint development. J Cell Biol 177 3 (2007) 451-464
104. Schipani E. Hypoxia and HIF-1 alpha in chondrogenesis. Semin Cell Dev Biol 16 4-5 (2005) 539-546
105. Chen E.Y., Fujinaga M., and Giaccia A.J. Hypoxic microenvironment within an embryo induces apoptosis and is essential for proper morphological development. Teratology 60 4 (1999) 215-225
106. Byrne A.M., Bouchier-Hayes D.J., and Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9 4 (2005) 777-794
107. Kojima H., Gu H., Nomura S., et al. Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha-deficient chimeric mice. Proc Natl Acad Sci USA 99 4 (2002) 2170-2174
108. Cramer T., Yamanishi Y., Clausen B.E., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112 5 (2003) 645-657
109. Makino Y., Nakamura H., Ikeda E., et al. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol 171 12 (2003) 6534-6540
110. Mobasheri A., Richardson S., Mobasheri R., Shakibaei M., and Hoyland J.A. Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. Histol Histopathol 20 4 (2005) 1327-1338
111. Semenza G.L. Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1. Exp Physiol 91 5 (2006) 803-806
112. Marrif H., and Juurlink B.H. Astrocytes respond to hypoxia by increasing glycolytic capacity. J Neurosci Res 57 2 (1999) 255-260
113. Hoppeler H., and Vogt M. Muscle tissue adaptations to hypoxia. J Exp Biol 204 Pt 18 (2001) 3133-3139
114. Tuomisto T.T., Rissanen T.T., Vajanto I., et al. HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis 174 1 (2004) 111-120
115. Ye G., Donthi R.V., Metreveli N.S., and Epstein P.N. Overexpression of hexokinase protects hypoxic and diabetic cardiomyocytes by increasing ATP generation. Cardiovasc Toxicol 5 3 (2005) 293-300
116. Ahmad A., Ahmad S., Schneider B.K., et al. Elevated expression of hexokinase II protects human lung epithelial-like A549 cells against oxidative injury. Am J Physiol Lung Cell Mol Physiol 283 3 (2002) L573-L584
117. Li D., Marks J.D., Schumacker P.T., Young R.M., and Brorson J.R. Physiological hypoxia promotes survival of cultured cortical neurons. Eur J Neurosci 22 6 (2005) 1319-1326
118. Zhu Y., Zhang Y., Ojwang B.A., Brantley Jr. M.A., and Gidday J.M. Long-term tolerance to retinal ischemia by repetitive hypoxic preconditioning: role of HIF-1alpha and heme oxygenase-1. Invest Ophthalmol Vis Sci 48 4 (2007) 1735-1743
119. Skoldenberg E.G., Christiansson J., Sandstedt B., et al. Angiogenesis and angiogenic growth factors in Wilms tumor. J Urol 165 6 Pt 2 (2001) 2274-2279
120. El-Houseini M.E., Abdel-Azim S.A., El-Desouky G.I., et al. Clinical significance of vascular endothelial growth factor (VEGF) in sera of patients with pediatric malignancies. J Egypt Natl Canc Inst 16 1 (2004) 57-61
121. Ghanem M.A., van Steenbrugge G.J., Sudaryo M.K., et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 56 2 (2003) 107-113
122. Nowicki M., Ostalska-Nowicka D., Kaczmarek M., Miskowiak B., and Witt M. The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour). Histopathology 50 3 (2007) 358-364
123. Shintani S., Kiyota A., Mihara M., et al. Association of preoperative radiation effect with tumor angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma. Jpn J Cancer Res 91 10 (2000) 1051-1057
124. Gee M.S., Koch C.J., Evans S.M., et al. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 59 19 (1999) 4882-4889
125. Kaya M., Wada T., Akatsuka T., et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6 2 (2000) 572-577
126. Yang Q.C., Zeng B.F., Dong Y., et al. Overexpression of hypoxia-inducible factor-1{alpha} in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol 37 2 (2007) 127-134
127. Onisto M., Slongo M.L., Gregnanin L., et al. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 27 3 (2005) 791-798
128. Komuro H., Kaneko S., Kaneko M., and Nakanishi Y. Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 127 12 (2001) 739-743
129. Holmquist-Mengelbier L., Fredlund E., Lofstedt T., et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10 5 (2006) 413-423
130. Huber H., Eggert A., Janss A.J., et al. Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer 37 16 (2001) 2064-2072
131. Ozer E., Sarialioglu F., Cetingoz R., et al. Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: a pediatric oncology group study. Pathol Res Pract 200 7-8 (2004) 501-509
132. Perez-Atayde A.R., Sallan S.E., Tedrow U., et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150 3 (1997) 815-821
133. Koomagi R., Zintl F., Sauerbrey A., and Volm M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res 7 11 (2001) 3381-3384
134. Avramis I.A., Panosyan E.H., Dorey F., Holcenberg J.S., and Avramis V.I. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from children's oncology group study CCG-1962. Clin Cancer Res 12 23 (2006) 6978-6984
135. de Bont E.S., Fidler V., Meeuwsen T., et al. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 8 9 (2002) 2856-2861
136. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 6 (2004) 437-447
137. Bachtiary B., Schindl M., Potter R., et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9 6 (2003) 2234-2240
138. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., and Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 2 (1997) 285-289
139. Moeller B.J., and Dewhirst M.W. HIF-1 and tumour radiosensitivity. Br J Cancer 95 1 (2006) 1-5
140. Williams K.J., Telfer B.A., Xenaki D., et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 75 1 (2005) 89-98
141. Voute P.A., van der Kleij A.J., De Kraker J., et al. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer A 31 4 (1995) 596-600
142. Bennett M., Feldmeier J., Smee R., and Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 4 (2005) CD005007
143. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6 10-11 (1994) 509-518
144. Padhani A.R. Where are we with imaging oxygenation in human tumours?. Cancer Imag 5 (2005) 128-130
145. Wartenberg M., Ling F.C., Muschen M., et al. Regulation of the multidrug resistance transporter p-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. Faseb J 17 3 (2003) 503-505
146. Comerford K.M., Wallace T.J., Karhausen J., et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62 12 (2002) 3387-3394
147. Teicher B.A., Lazo J.S., and Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41 1 (1981) 73-81
148. Brown J.M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67 6 (1993) 1163-1170
149. Peters K.B., and Brown J.M. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62 18 (2002) 5248-5253
150. Yang B., and Reynolds C.P. Tirapazamine cytotoxicity for neuroblastoma is p53 dependent. Clin Cancer Res 11 7 (2005) 2774-2780
151. Wouters B.G., Delahoussaye Y.M., Evans J.W., et al. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res 61 1 (2001) 145-152
152. Langmuir V.K., Rooker J.A., Osen M., Mendonca H.L., and Laderoute K.R. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res 54 11 (1994) 2845-2847
153. Lartigau E., and Guichard M. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br J Cancer 73 12 (1996) 1480-1485
154. el-Said A., Menke D., Dorie M.J., and Brown J.M. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation. Radiat Oncol Investig 7 3 (1999) 163-169
155. Lunt S.J., Telfer B.A., Fitzmaurice R.J., Stratford I.J., and Williams K.J. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin Cancer Res 11 11 (2005) 4212-4216
156. Rischin D., Peters L., Hicks R., et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19 2 (2001) 535-542
157. Le Q.T., McCoy J., Williamson S., et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a southwest oncology group study. Clin Cancer Res 10 16 (2004) 5418-5424
158. Aquino V.M., Weitman S.D., Winick N.J., et al. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study. J Clin Oncol 22 8 (2004) 1413-1419
159. Rischin D., Hicks R.J., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-Tasman radiation oncology group study 98.02. J Clin Oncol 24 13 (2006) 2098-2104
160. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized Phase II trial of the trans-Tasman radiation oncology group (TROG 98.02). J Clin Oncol 23 1 (2005) 79-87
161. Gatineau M., Rixe O., and Chevalier T.L. Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a Phase I/II study. Clin Lung Cancer 6 5 (2005) 293-298
162. Williamson S.K., Crowley J.J., Lara Jr. P.N., et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: southwest oncology group trial S0003. J Clin Oncol 23 36 (2005) 9097-9104
163. Patterson L.H., and McKeown S.R. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 83 12 (2000) 1589-1593
164. Patterson L.H. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 34 3 (2002) 581-592
165. Patterson L.H., McKeown S.R., Ruparelia K., et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 82 12 (2000) 1984-1990
166. McKeown S.R., Friery O.P., McIntyre I.A., et al. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer Suppl 27 (1996) S39-S42
167. Gallagher R., Hughes C.M., Murray M.M., et al. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 85 4 (2001) 625-629
168. Papadopoulou M.V., Ji M., Ji X., Bloomer W.D., and Hollingshead M.G. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chemother Pharmacol 50 6 (2002) 501-508
169. Papadopoulou M.V., Ji M., Bloomer W.D., and Hollingshead M.G. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts. J Exp Ther Oncol 2 5 (2002) 298-305
170. Steward W., Middleton M., Benghiat A., et al. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a Phase I study. Ann Oncol 18 6 (2007) 1098-1103
171. Tang N., Wang L., Esko J., et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6 5 (2004) 485-495
172. Li L., Lin X., Staver M., et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 65 16 (2005) 7249-7258
173. Mizuno T., Nagao M., Yamada Y., et al. Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther 13 2 (2006) 131-140
174. Zhang Q., Zhang Z.F., Rao J.Y., et al. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer 111 6 (2004) 849-857
175. Stoeltzing O., McCarty M.F., Wey J.S., et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 96 12 (2004) 946-956
176. Weigel B.J., Blaney S.M., Reid J.M., et al. A Phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a children's oncology group study. Clin Cancer Res 13 6 (2007) 1789-1793
177. Bagatell R., Gore L., Egorin M.J., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13 6 (2007) 1783-1788
178. Sharp S., and Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95 (2006) 323-348
179. Soffer S.Z., Moore J.T., Kim E., et al. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg 36 8 (2001) 1177-1181
180. Kim B.S., Chen J., Weinstein T., Noiri E., and Goligorsky M.S. VEGF expression in hypoxia and hyperglycemia: reciprocal effect on branching angiogenesis in epithelial-endothelial co-cultures. J Am Soc Nephrol 13 8 (2002) 2027-2036
181. McCrudden K.W., Yokoi A., Thosani A., et al. Topotecan is anti-angiogenic in experimental hepatoblastoma. J Pediatr Surg 37 6 (2002) 857-861
182. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metast Rev 26 2 (2007) 341-352
183. Welsh S., Williams R., Kirkpatrick L., Paine-Murrieta G., and Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3 3 (2004) 233-244
184. Chau N.M., Rogers P., Aherne W., et al. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res 65 11 (2005) 4918-4928
185. Carroll V.A., and Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66 12 (2006) 6264-6270
186. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 6 4 (2007) 273-286
187. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 15 (2005) 3502-3508
188. Shih T., and Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28 11 (2006) 1779-1802
189. Chakraborty G., Rangaswami H., Jain S., and Kundu G.C. Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem 281 16 (2006) 11322-11331
190. Rowe D.H., Huang J., Kayton M.L., et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 35 1 (2000) 30-32 [Discussion 2-3]
191. Segerstrom L., Fuchs D., Backman U., et al. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res 60 5 (2006) 576-581
192. Rowe D.H., Huang J., Li J., et al. Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg 35 6 (2000) 977-981
193. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13 13 (2007) 3942-3950
194. Tyagi P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 5 1 (2005) 24-26
195. Los M., Roodhart J.M., and Voest E.E. Target practice: lessons from Phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12 4 (2007) 443-450
196. Maris J.M., Courtright J., Houghton P.J., et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer (2007)
197. Robertson N., Potter C., and Harris A.L. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 64 17 (2004) 6160-6165
198. Teicher B.A., Liu S.D., Liu J.T., Holden S.A., and Herman T.S. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 13 5A (1993) 1549-1556
199. Vullo D., Franchi M., Gallori E., et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 13 6 (2003) 1005-1009
200. Pastorekova S., Casini A., Scozzafava A., et al. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 14 4 (2004) 869-873
201. Cecchi A., Taylor S.D., Liu Y., et al. Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett 15 23 (2005) 5192-5196
202. Innocenti A., Villar R., Martinez-Merino V., et al. Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides. Bioorg Med Chem Lett 15 21 (2005) 4872-4876
203. Pande A., Lombardo J., Spangenthal E., and Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 27 5B (2007) 3465-3470
204. Stempak D., Gammon J., Halton J., et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 28 11 (2006) 720-728
205. Baruchel S., Diezi M., Hargrave D., et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42 14 (2006) 2335-2342
206. Emmenegger U., Man S., Shaked Y., et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64 11 (2004) 3994-4000
207. Kong D., Park E.J., Stephen A.G., et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65 19 (2005) 9047-9055
208. Tan C., de Noronha R.G., Roecker A.J., et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65 2 (2005) 605-612
209. Rapisarda A., Uranchimeg B., Scudiero D.A., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62 15 (2002) 4316-4324
210. Lau C.K., Yang Z.F., Lam C.T., et al. Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochem Biophys Res Commun 348 4 (2006) 1443-1448
211. Chun Y.S., Yeo E.J., Choi E., et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 61 8 (2001) 947-954
212. Yeo E.J., Chun Y.S., Cho Y.S., et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95 7 (2003) 516-525
213. Shin D.H., Kim J.H., Jung Y.J., et al. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 255 1 (2007) 107-116
214. Welsh S.J., Bellamy W.T., Briehl M.M., and Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62 17 (2002) 5089-5095
215. Welsh S.J., Williams R.R., Birmingham A., et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2 3 (2003) 235-243
216. Ramanathan R.K., Kirkpatrick D.L., Belani C.P., et al. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res 13 7 (2007) 2109-2114
217. Mabjeesh N.J., Escuin D., LaVallee T.M., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 4 (2003) 363-375
218. Lakhani N.J., Sarkar M.A., Venitz J., and Figg W.D. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23 2 (2003) 165-172
219. Rapisarda A., Zalek J., Hollingshead M., et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64 19 (2004) 6845-6848
220. Kamiyama H., Takano S., Tsuboi K., and Matsumura A. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 131 4 (2005) 205-213
221. Kung A.L., Zabludoff S.D., France D.S., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 1 (2004) 33-43
222. Jones D.T., and Harris A.L. Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol Cancer Ther 5 9 (2006) 2193-2202
223. Newcomb E.W., Ali M.A., Schnee T., et al. Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro Oncol 7 3 (2005) 225-235
224. Shapiro G.I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 10 12 Pt 2 (2004) 4270s-4275s
225. Cao Z., Fang J., Xia C., Shi X., and Jiang B.H. trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 10 15 (2004) 5253-5263
226. Han J.Y., Oh S.H., Morgillo F., et al. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97 17 (2005) 1272-1286
227. Blum R., Jacob-Hirsch J., Amariglio N., Rechavi G., and Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 65 3 (2005) 999-1006
228. Fang J., Cao Z., Chen Y.C., Reed E., and Jiang B.H. 9-Beta-d-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells. Mol Pharmacol 66 1 (2004) 178-186